Botulinum Toxin-A for Hidradenitis Suppurativa
Reason given: Study never officially began (or enrolled)
Key facts
- Where
- Guilford, United StatesSee the site
- Phase
- Phase 4
Where in United States
- Yale Medicine Multispecialty ClinicGuilford, United StatesNo longer taking part
Trial details
- Who runs it
- Yale University
- Trial code
- NCT06237465
- Record updated
- 16 December 2025
- Original description
The purpose of this research study is to determine if the medication Botulinum Toxin-A (BTX-A) is effective in treating hidradenitis suppurativa (HS)Read full original descriptionShow less
The purpose of this research study is to determine if the medication Botulinum Toxin-A (BTX-A) is effective in treating hidradenitis suppurativa (HS)
Inclusion: Subjects with active axillary hidradenitis suppurativa of the same severity bilaterally. regimen; For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation; Agreement to forego other treatments for hidradenitis for the duration of the study.
Exclusion: Current use of antibiotics, hormonal therapies, steroids, and/or biologics; Treatment with another investigational drug or other intervention within three months; Presence of cardiac pacemaker; Known neuromuscular disorder; Febrile illness within one month; Pregnancy or lactation; Known hyperhidrosis; Patients without active axillary hidradenitis suppurativa.